...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Korean medical science >Current smoking is associated with a poor visual acuity improvement after intravitreal ranibizumab therapy in patients with exudative age-related macular degeneration
【24h】

Current smoking is associated with a poor visual acuity improvement after intravitreal ranibizumab therapy in patients with exudative age-related macular degeneration

机译：玻璃体腔注射兰尼单抗治疗后渗出的年龄相关性黄斑变性患者当前吸烟与视力改善不良有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this study, the risk factors that may influence visual improvement after intravitreal ranibizumab (IVR) treatment for exudative age-related macular degeneration (AMD) wereexamined. From 2008 to 2012, 420 patients (448 eyes) with exudative AMD were prospectively registered at Seoul National University Hospital. From this group of patients,125 eyes were included in this study. All patients were treated with 3 consecutive IVRinjections. The visual acuity (VA) was evaluated at baseline and 1 month after the thirdranibizumab injection. To evaluate the risk factors associated with VA improvement afterIVR, patient demographic data and systemic risk factors were analyzed. Patients were divided into a poorVA improvement group and a good VA improvement group, withreference to the median visual improvement in all eyes. Among125 eyes, 66 eyes (52.8%)were included in the responder group and 59 eyes (47.2%) in the non-responder group.The medianVA improvement after 3 monthly ranibizumab injections was -0.05 logMAR.Multivariate analyses revealed that current smoking (adjusted OR, 7.540; 95% CI, 1.732-32.823) was independently associated with poor VA improvement after IVR treatment forexudative AMD. In conclusion, cigarette smoking is an independent risk factor for lower VA gains with IVR treatment for exudative AMD.
机译：在这项研究中，风险因素可能会影响玻璃体腔注射兰尼单抗（IVR）治疗渗出性年龄相关性黄斑变性（AMD）后的视力改善。从2008年至2012年，在首尔国立大学医院前瞻性登记了420例渗出性AMD患者（448眼）。在该组患者中，本研究纳入了125只眼。所有患者均接受连续3次IVR注射治疗。在基线和第三次ranibizumab注射后1个月评估视力（VA）。为了评估IVR后VA改善相关的危险因素，分析了患者的人口统计数据和系统性危险因素。根据所有眼睛的中位视力改善情况，将患者分为不良VA改善组和良好VA改善组。在125只眼中，有反应者组包括66只眼（52.8％），无反应者组中有59只眼（47.2％）。兰尼单抗每月3次注射后的VA中位数改善为-0.05 logMAR。多因素分析显示当前吸烟（调整后） OR，7.540; 95％CI，1.732-32.823）与IVR治疗渗出性AMD后的VA改善不良独立相关。总之，吸烟是渗出性AMD的IVR治疗降低VA增高的独立危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号